Fulvestrant is a hormonal treatment for metastatic breast cancer. It is suitable for postmenopausal women with progression following other hormonal therapy.
What is this medication used for
Fulvestrant is a hormonal treatment for metastatic breast cancer. It is suitable for postmenopausal women with progression following other hormonal therapy.
Dosage and How to Use
It is given once a month as an intramuscular injection in the buttock.
Side Effects, Precautions, Contraindication
What are the side effects of Fulvestrant?
- Bone and back pain
May be relieved by taking paracetamol
- Headache and dizziness may occur
Inform your doctor if any of the following occurs:
- Persistent bone and back pain
- Chest pain and rapid, irregular heartbeat
- Unusual weight gain (>3kg/week)
- Cough with difficulty breathing
- Painful or burning urination
- Other persistent or severe side effects
Handling and Storage
Keep it in the refrigerator between 2 - 8°C. Do not freeze.
Additional Information
Other name: Faslodex®
If you have any questions, please call your pharmacist at the National Cancer Centre. The side effects listed above are those that occur frequently. Other side effects may occur. Please contact your doctor to report.
Disclaimer: The National Cancer Centre Singapore does not endorse or promote the use of any product mentioned in this booklet. The information is presented in a summary to provide an understanding and for knowledge only, and may not contain information about all aspects of care. It does not recommend self-management of health problems or replace consultation with your doctor. You should never disregard medical advice or delay seeking treatment because of something you have read in this booklet.
©2012
Copyright © National Cancer Centre Singapore
All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without prior written permission from the publisher.
Document No. PHM-MED-PEM-093/0916
Version 1
Last reviewed: July 2017
Produced by Department of Pharmacy
National Cancer Centre Singapore